Infigratinib phosphate is under clinical development by QED Therapeutics and currently in Phase III for Achondroplasia. According to GlobalData, Phase III drugs for Achondroplasia have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Infigratinib phosphate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Infigratinib phosphate overview

Infigratinib phosphate (Truseltiq) is an anti-neoplastic agent. It is formulated as hard gelatin capsules for oral route of administration. Truseltiq is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.

Infigratinib phosphate (BGJ-398) is under development for the treatment of hematologic malignancies, advanced or metastatic cholangiocarcinoma, gastric cancer, adenocarcinoma of the gastroesophageal junction, prostate cancer, thyroid cancer, breast cancer, liver cancer, glioblastoma multiforme, hypochondroplasia and achondroplasia. The drug candidate is administered orally as a capsule. It targets pan-fibroblast growth factor receptor (FGFR). It was also under development for the treatment of solid tumors including recurrent glioblastoma multiforme (GBM), advanced gastrointestinal stromal tumor (GIST). It was under development for head and neck squamous cell carcinoma including nasopharyngeal cancer, muscle-invasive bladder cancer, urothelial carcinoma, progressive low-grade glioma and tumor-induced osteomalacia.

It was under development for high-grade glioma.

QED Therapeutics overview

QED Therapeutics, a subsidiary of BridgeBio Pharma Inc, is a biotechnology company focused on precision medicine for treatment of achondroplasia. The company is headquartered in Palo Alto, California, the US.

For a complete picture of Infigratinib phosphate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.